II
BEAT

Ibex Investors’s BioTelemetry, Inc. BEAT Stock Holding History

Ibex Investors’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,959
Closed -$237K – 167
2018
Q4 		$237K Buy
3,959
+574
+17% +$34.5K 0.04% 63
2018
Q3 		$218K Buy
+3,385
New +$189K 0.12% 67

Other funds holding BEAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ibex Investors's BEAT Position: Q1 2019 in Review

Ibex Investors sold out of BioTelemetry, Inc. (BEAT) in Q1 2019, closing a stake of 3,959 shares — an estimated $237K sold.

Ibex Investors first reported a position in BEAT in Q3 2018 and held it in 2 quarters. The position peaked at $237K in Q4 2018. 311 funds tracked by Wall St. Rank hold BEAT as of Q1 2019.

  • Ibex Investors reported no remaining BioTelemetry, Inc. position as of Q1 2019 after selling out during the quarter.
  • Ibex Investors sold 3,959 BioTelemetry, Inc. shares in Q1 2019, an estimated $237K.
  • Ibex Investors first reported a position in BioTelemetry, Inc. in Q3 2018 and held it in 2 quarters.
  • Ibex Investors's BioTelemetry, Inc. position peaked at $237K in Q4 2018.
  • 311 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.